VEGFA and neoplasm: Sustained hypoxia by sunitinib ‘resets’ the tumor microenvironment and leads to the development of a VEGF/VEGFR-independent alternate angiogenic pathway through the up-regulation of angiogenic factors other than VEGF (60, 83).